WO2011072141A1 - Compositions and methods for the treatment of macular degeneration - Google Patents

Compositions and methods for the treatment of macular degeneration Download PDF

Info

Publication number
WO2011072141A1
WO2011072141A1 PCT/US2010/059719 US2010059719W WO2011072141A1 WO 2011072141 A1 WO2011072141 A1 WO 2011072141A1 US 2010059719 W US2010059719 W US 2010059719W WO 2011072141 A1 WO2011072141 A1 WO 2011072141A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
cyclodextrin
macular degeneration
compounds
composition
Prior art date
Application number
PCT/US2010/059719
Other languages
French (fr)
Inventor
Thomas A. Jordan
John Clifford Chabala
Gerald D. Cagle
Original Assignee
Neuron Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuron Systems, Inc. filed Critical Neuron Systems, Inc.
Priority to US13/514,769 priority Critical patent/US9814701B2/en
Priority to JP2012543284A priority patent/JP5885670B2/en
Priority to CA2782015A priority patent/CA2782015C/en
Publication of WO2011072141A1 publication Critical patent/WO2011072141A1/en
Priority to US15/782,470 priority patent/US20180092882A1/en
Priority to US18/241,598 priority patent/US12097188B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Definitions

  • Macular degeneration is a leading cause of progressive blindness.
  • the macula is the central region of the retina and contains the fovea where high acuity central vision is processed.
  • Macular degeneration is a neurodegenerative disease in the macula that progressively causes disabling deficits in visual function.
  • Age-related macular degeneration is the most common form and first appears at middle age or later.
  • AMD age-related macular degeneration
  • FAF fundus auto-fluorescence
  • RPE retinal pigment epithelial
  • A2E is a reaction product of all- trans retinaldehyde (RAL) and phosphatidylethanolamine (PE), a membrane phospholipid found in the disc membranes of photoreceptor outer segments.
  • the RAL that reacts with PE escapes from the visual cycle (step 3b in Figure 1), a metabolic pathway in the back of the eye that (i) converts vitamin A from an alcohol (retinol) to a photo-reactive aldehyde (1 ⁇ -cis- retinaldehyde) for use in photo-transduction by opsin proteins in photoreceptor cell outer segments, and (ii) converts RAL to retinol after photo-transduction.
  • retinol an alcohol
  • a photo-reactive aldehyde (1 ⁇ -cis- retinaldehyde
  • RAL converts RAL to retinol after photo-transduction.
  • A2E precursors form reversibly in photoreceptor outer segments, which are ingested by neighboring RPE cells after diurnal shedding.
  • A2E The final and irreversible step in the biosynthesis of A2E takes place in the acidic environment of RPE cell lysosomes.
  • A2E accumulates in RPE cells, it gradually poisons them by multiple cytotoxic mechanisms including lysosomal failure. This leads to the accumulation of undigested cellular debris called lipofuscin, which contains A2E and can be detected clinically by FAF.
  • lipofuscin As RPE cells deteriorate, they lose their ability to participate in the visual cycle and are unable to provide photoreceptors with other metabolic support required for normal retinal function (see Figure 1 ; Lamb TD, Pugh EN, Dark adaptation and the retinoid cycle of vision. Prog. Retinal and Eye Res. 2004;23 :307). As their metabolic support is withdrawn, photoreceptors fail to renew their shed outer segments and visual function is progressively lost. Reducing A2E formation will allow RPE cells to recover from A2E poisoning and resume their normal metabolic support of photoreceptor cells.
  • WO 2006/127945 discloses compounds and compositions that have been shown to reduce the formation of A2E, which as described above is the underlying etiology of macular degeneration including dry AMD and Stargardt's disease. These compounds are designed to inhibit A2E biosynthesis by reducing the amount of free RAL available for reaction with PE in photoreceptor outer segments, which is the first step in the A2E biosynthetic pathway. These compounds are lipophilic by design (i.e.
  • logP or clogP which are called logD or clogD respectively at pH 7.4 as used herein
  • logP or clogP which are called logD or clogD respectively at pH 7.4 as used herein
  • a different way to reduce A2E biosynthesis is to inhibit one or more proteins of the visual cycle, because when the visual cycle is inhibited, less RAL escapes the visual cycle and becomes available to react with PE and form A2E precursors.
  • Chronic treatment with a visual cycle inhibitor has been shown to reduce A2E synthesis in mouse (Radu et al, Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci U S A. 2003; 100:4742).
  • neuroprotection mechanisms of action including but not limited to neurotrophic receptor agonists, anti-inflammatory compounds including complement cascade inhibitors, anti- apoptosis compounds, steroids and anti-oxidant compounds, and limiting the progression to wet AMD with VEGF receptor blockers which mitigate the effects of VEGF signaling by RPE cells that are in severe oxidative stress as a consequence of A2E toxicities.
  • topical ocular administration minimizes systemic exposure compared to oral dosing.
  • the present invention provides formulations and methods for topical ocular dosing of lipophilic compounds which treat macular degeneration (including dry AMD, GA secondary to dry AMD, wet AMD and Stargardt's disease) by reducing the formation of A2E and other naturally occurring bis-retinoids, by reacting covalently with free RAL that escapes the visual cycle and would otherwise form precursors of these compounds.
  • Figure 1 depicts the visual cycle.
  • Figure 2 depicts a time profile of the concentration of 14 C-Compound A in ng/g of ocular tissue.
  • Figure 3 depicts effects of RA treatment on dark adaptation rate in the mouse after acute TO or IP administration of 13-czs-retinoic acid.
  • One embodiment of the present invention provides pharmaceutical compositions for treating macular degeneration (including dry AMD, GA secondary to dry AMD, wet AMD and Stargardt's disease).
  • macular degeneration including dry AMD, GA secondary to dry AMD, wet AMD and Stargardt's disease.
  • the root cause of macular degeneration is the cytotoxic accumulation in RPE cells of naturally occurring bis-retinoids including A2E. This accumulation can be lowered pharmacologically by limiting the amount of free RAL that escapes the visual cycle and otherwise reacts with PE to form their precursors. As the accumulation of these compounds is reduced pharmacologically, RPE cells can recover from cytotoxic damage and resume their metabolic support of photoreceptors which is essential for normal visual function.
  • publications WO 2006/127945 compounds are described which reduce A2E accumulation in this manner and are therefore useful in treating macular degeneration.
  • the instant application incorporates by reference the subject matter of WO 2006/127945.
  • Lipophilic compounds which reduce A2E and thereby treat macular degeneration including dry AMD and Stargardt's disease by other means (e.g. by inhibiting the visual cycle) are also included within the scope of this invention.
  • Such compounds include ACU-4429. All such compounds have a logP or clogP greater than 0.
  • topical ocular administration minimizes systemic exposure compared to oral dosing.
  • most topical formulations have failed to deliver efficacious levels of drug to the retina which is the site of the mechanism of action.
  • a lipophilic active agent and a cyclodextrin, or chemically modified cyclodextrin including trimethyl- ⁇ - cyclodextrin, 2-hydroxyethyl-P-cyclodextrin, 2-hydroxypropyl-P-cyclodextrin, 3- hydroxypropyl-P-cyclodextrin, and ⁇ -cyclodextrin sulfobutylether sodium salt (or potassium salt)
  • efficacious levels of the lipophilic active agent are delivered to the back of the eye and specifically to the RPE and retina.
  • compositions of a lipophilic active agent and an oligomeric or a polymeric carrier such as a cyclodextrin or chemically modified cyclodextrin including trimethyl-P-cyclodextrin, 2-hydroxyethyl-p-cyclodextrin, 2- hydroxypropyl-P-cyclodextrin, 3-hydroxypropyl-P-cyclodextrin, and ⁇ -cyclodextrin sulfobutylether sodium salt (or potassium salt) are useful for the treatment of macular degeneration (including dry age-related macular degeneration, GA secondary to dry AMD, wet AMD and Stargardt's disease).
  • macular degeneration including dry age-related macular degeneration, GA secondary to dry AMD, wet AMD and Stargardt's disease.
  • One exemplification of the present invention is represented by a topical ophthalmic composition containing an active lipophilic compound and an oligomeric or a polymeric carrier such as a cyclodextrin, or a chemically modified cyclodextrin including trimethyl-p-cyclodextrin, 2-hydroxyethyl- -cyclodextrin, 2-hydroxypropyl-P-cyclodextrin, 3- hydroxypropyl-P-cyclodextrin, and ⁇ -cyclodextrin sulfobutylether sodium salt (or potassium salt) in an aqueous solution or a gel dispersion.
  • an active lipophilic compound and an oligomeric or a polymeric carrier
  • an oligomeric or a polymeric carrier such as a cyclodextrin, or a chemically modified cyclodextrin including trimethyl-p-cyclodextrin, 2-hydroxyethyl- -cyclodextrin, 2-
  • Such active lipophilic compounds include those that reduce A2E by reacting covalently with RAL, e.g. the compounds of WO 2006/127945.
  • Illustrative of such compounds are those described in WO 2006/127945 the contents of which application are herein incorporated by reference.
  • Exemplifying the compounds which may be employed in the instant invention are the compounds of formula
  • X, Y, and Z are each, independently, N, CH, C with the NH 2 attached, or absent, such that one of X, Y, and Z is N; p is 0, 1, 2, or 3,
  • B is a halogen atom, hydroxyl, carbamoyl, amino, or aryl, A is s D is unbranched lower alkyl.
  • compound A of paragraph (00027) of WO 2006/ 127945 and pharmaceutically acceptable salts thereof may be employed in the instant invention.
  • L is a single bond or CH 2 ;
  • X, Y, and Z are each, independently, N, NH, O, S, CB, CH, or absent, such that one of X, Y, and Z is N or
  • the amount of active agent in the composition will vary dependent on the intrinsic activity of the compound. However, for compounds of formula la and formula Ilia the amount will generally be from 0.01-1.0% weight/volume and more particularly 0.1% to 0.5% weight/volume.
  • a compound as described above may be used or a pharmaceutically acceptable salt of said compound.
  • the term lipophilic compound is meant to include the compound and its pharmaceutically acceptable salts.
  • a pharmaceutically acceptable salt herein means a salt that is capable of being topically delivered to the eye of a patient.
  • the carrier in the composition is an oligomeric or a polymeric carrier such as a cyclodextrin including trimethyl-p-cyclodextrin, 2-hydroxyethyl ⁇ -cyclodextrin, 2- hydroxypropyl- -cyclodextrin, 3-hydroxypropyl-P-cyclodextrin, and ⁇ -cyclodextrin sulfobutylether sodium salt (or potassium salt).
  • a cyclodextrin including trimethyl-p-cyclodextrin, 2-hydroxyethyl ⁇ -cyclodextrin, 2- hydroxypropyl- -cyclodextrin, 3-hydroxypropyl-P-cyclodextrin, and ⁇ -cyclodextrin sulfobutylether sodium salt (or potassium salt).
  • ⁇ -cyclodextrin sulfobutylether sodium salt Exemplifying an oligomeric or a polymeric carrier is ⁇ -cyclod
  • the amount of ⁇ -cyclodextrin sulfobutylether sodium salt in the aqueous preparation may range from about 0.01% to 30% weight/volume. In one illustration the concentration of ⁇ -cyclodextrin sulfobutylether sodium salt is 5-25% weight/volume. Further illustrating the concentration of ⁇ -cyclodextrin sulfobutylether sodium salt is 9.5-20%) weight/volume. In one exemplification the concentration of ⁇ -cyclodextrin sulfobutylether is 9.5% weight/volume.
  • each lipophilic agent may be formulated with each of the excipients.
  • the composition may contain saline and be buffered with for example a phosphate buffer so that the pH of the composition is brought to a pH range of 5.5-8.5 or more particularly a pH of 6.5-7.5.
  • a preservative may optionally be included in the composition. Such preservatives can include both chemical stabilizers and antiseptics.
  • Compounds such as Compounds A are stable under the conditions of use, however other compounds may require the use of other excipients such as anti-oxidants.
  • a second embodiment of the invention is directed to a method of treating macular degeneration (including dry age-related macular degeneration, GA secondary to dry AMD, wet AMD and Stargardt's disease), by administering a topical formulation of an active lipophilic compound and a carrier to the eye(s) of a patient.
  • macular degeneration including dry age-related macular degeneration, GA secondary to dry AMD, wet AMD and Stargardt's disease
  • the present invention provides a topical ophthalmic composition for use in treating macular degeneration wherein said composition comprises an active lipophilic compound and a carrier or a pharmaceutically acceptable salt thereof in an aqueous solution.
  • Exemplifying the carrier is ⁇ -cyclodextrin sulfobutylether or a pharmaceutically acceptable sat thereof.
  • the active lipophilic compound in each of these embodiments includes those that reduce A2E by reacting with RAL, e.g. the compounds of WO 2006/127945. Examples of such compounds are those described in WO 2006/127945. Exemplifying such compounds are Compounds A, B and C. Lipophilic Compounds which function by other mechanisms such as ACU-4429 are also included.
  • the term lipophilic compound is meant to include both the compound and its pharmaceutically acceptable salts.
  • the excipient in the formulation is oligomeric or polymeric such as a cyclodextrin or a chemically modified cyclodextrin, more particularly including ⁇ -cyclodextrin sulfobutylether sodium salt (or potassium salt).
  • each lipophilic compound formulated with each excipient.
  • the formulation may be buffered to a pH range of 5.5-8.5 or more particularly a pH of 6.5-7.5.
  • the buffer may be a phosphate buffer.
  • the formulation may be applied as an aqueous solution or a gel dispersion and the solution may be a saline solution. The accumulation of lipofuscin occurs in RPE cells in the back of the eye.
  • topical compositions as described herein deliver pharmacologically active levels of lipophilic active drug safely to the back of the eye after topical ocular administration and are therefore useful in the treatment of macular degeneration (including dry age-related macular degeneration, GA secondary to dry AMD, wet AMD and Stargardt's disease). Efficacious levels are defined as those that reduce A2E accumulation significantly in animal studies.
  • Formulations of a lipophilic active agent and an oligomeric or a polymeric carrier are prepared by stirring an aqueous suspension or solution of a polymeric carrier such as a cyclodextrin, or chemically modified cyclodextrin including trimethyl- -cyclodextrin, 2- hydroxyethyl- -cyclodextrin, 2-hydroxypropyl-P-cyclodextrin, 3-hydroxypropyl-P- cyclodextrin, and ⁇ -cyclodextrin sulfobutylether sodium (or potassium) salt with water, saline or phosphate-buffered saline at a temperature from 20°C to 50°C, but preferably at ambient temperature, for 0.1 -24 hr, depending on the polymeric carrier.
  • a polymeric carrier such as a cyclodextrin, or chemically modified cyclodextrin including trimethyl- -cyclodextrin, 2- hydroxyethyl
  • the lipophilic active agent is added as a solid or neat liquid to the thus formed aqueous suspension or solution of polymeric carrier, and the resulting mixture is stirred at a temperature from 20°C to 50°C, but preferably at ambient temperature, for 0.1-24 hr, but typically from 0.5-2 hr, depending on the lipophilic active agent.
  • the thus formed formulation of a lipophilic active agent and an oligomeric or a polymeric carrier may then be treated with an aqueous solution of an inorganic or organic acid or an inorganic or organic base to adjust the pH of the solution as desired.
  • preservatives including both chemical stabilizers and antiseptics.
  • Example 1 Preparation of a 0.1% w/v aqueous formulation of Compound A with 9.5% w/v ⁇ -cyclodextrin sulfobutylether.
  • the preparation was carried out in a 1000 ml beaker equipped with a stirring bar for mixing. Approximately 60% of the targeted weight of sterile water was added to the beaker. Stirring was adjusted so as not to incorporate air. Anhydrous dibasic sodium phosphate (0.83% of the total batch weight) and sodium phosphate monobasic monohydrate (0.017% of the total batch weight) was added to the vessel and mixed until dissolved, ⁇ - cyclodextrin sulfobutylether (9.5% of the total batch weight) was slowly added to the beaker and the solution mixed until dissolved. Compound A (0.1% of the total batch weight) was slowly added and mixed until dissolved. A sample was extracted and the pH measured. If the pH was not in the range 7.3 ⁇ 0.05 , adjustment was made with IN aqueous NaOH or IN aqueous HC1. The batch weight was measured and the amount of sterile water needed to bring to final batch weight was determined and added.
  • the target tissue for the biological activity of compounds which reversibly react with RAL, e.g. Compounds A, B and C, is the outer segment of retinal photoreceptor cells.
  • TO topical optical
  • Compound A delivers therapeutically useful amounts of, for example, Compound A to the retina
  • C57BL/6 mice, the parent strain of abcr -I- mice (knockout mouse) were treated intraperitoneal ly (IP) with 14 C-Compound A at 10 mg/kg ("efficacious dose"), specifically a dose that when repeated daily for 56 days reduced A2E formation by 71% (p ⁇ 0.01) in the abcr -I- mouse.
  • the eyes of the mice were enucleated and the posterior eyecup was dissected, extracted and analyzed by liquid scintillation chromatography (LSC) for ,4 C-Compound A.
  • LSC liquid scintillation chromatography
  • PK pharmacokinetics
  • Compound A in four intraocular regions of Cynomolgus Macaques was measured after topical dosing of 40 ⁇ per eye of 0.50% weight/volume 1 C-Compound A in ⁇ -cyclodextrin sulfobutylether sodium salt in phosphate- buffered saline.
  • Sampling of intraocular regions (vitreous humor, retina+RPE, anterior eyecup, and posterior eyecup) and blood for PK evaluation was conducted at 0.25, 0.5, 1, 3, 6 and 9 hours post dose.
  • Figure 2 shows the time course of 14 C-Compound A concentration expressed in nanograms (ng ) per gram (g) of ocular tissue.
  • retinoids can be used to demonstrate that a small lipophilic compound in a composition containing ⁇ -cyclodextrin sulfobutylether sodium salt exhibits biological activity in the retina minutes to hours after topical application to the front of the eye.
  • a retinoid useful for this purpose is 13-m-retinoic acid (RA, also known as isotretinoin).
  • RA 13-m-retinoic acid
  • Mice treated IP at 20 mg/kg with RA show visual cycle inhibition ( Figure 3).
  • Independent studies demonstrate that the visual cycle inhibition decreases A2E synthesis (Radu RA, Mata NL, Nusinowitz S, Liu X, Sieving PA, Travis GH.
  • Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci 2003;100:4742).
  • mice treated TO with one or two 30 eyedrops of a composition containing 0.2% weight/volume RA and 20% weight/volume ⁇ -cyclodextrin sulfobutylether sodium salt in phosphate-buffered saline showed a dose-responsive inhibition of DA similar to that observed after IP dosing ( Figure 3) ⁇

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic compound and an oligomeric or polymeric carrier.

Description

COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR
DEGENERATION
Related Application
[0001] This application claims the benefit of U.S. Provisional Application No. 61/285,745, filed December 1 1, 2009, the entire contents of which is incorporated herein by reference.
Background of the Invention
[0002] Macular degeneration is a leading cause of progressive blindness. The macula is the central region of the retina and contains the fovea where high acuity central vision is processed. Macular degeneration is a neurodegenerative disease in the macula that progressively causes disabling deficits in visual function.
[0003] There are multiple forms of macular degeneration. Age-related macular degeneration (AMD) is the most common form and first appears at middle age or later. In AMD patients, the dry form normally occurs first and develops with no vascular complications. Its clinical signs include an increase in fundus auto-fluorescence (FAF) and the formation of extracellular deposits called soft drusen, both caused by the accumulation of lipofuscin in retinal pigment epithelial (RPE) cells as discussed below. About 40% of dry AMD patients progress to an advanced form of the disease called geographic atrophy (GA) secondary to dry AMD, which is characterized by one or more atrophic retinal lesions caused by the localized death of RPE cells and adjacent retinal photoreceptor cells. Another 10% of dry AMD patients progress to wet AMD, which is characterized by neovascular growth from the choroid into the retina in response to VEGF signaling by RPE cells that are undergoing severe oxidative stress from A2E toxicities. Choroidal neovascular growth disrupts retinal tissue and destroys visual function in regions of the macula where this occurs. Finally, there is an early onset form of macular degeneration called Stargardt's disease which first appears in teenagers and young adults. Stargardt's disease is believed to have the same etiology as dry AMD.
[0004] Multiple lines of evidence indicate that macular degeneration is caused by the cytotoxic accumulation in RPE cells of naturally occurring bis-retinoid compounds including A2E (Sparrow JR, Wu Y, Kim CY, Zhou J. Phospholipid meets all-trans-retinal: the making of RPE bisretinoids. J Lipid Res. 2009 Aug 7 e-published). A2E is a reaction product of all- trans retinaldehyde (RAL) and phosphatidylethanolamine (PE), a membrane phospholipid found in the disc membranes of photoreceptor outer segments. The RAL that reacts with PE escapes from the visual cycle (step 3b in Figure 1), a metabolic pathway in the back of the eye that (i) converts vitamin A from an alcohol (retinol) to a photo-reactive aldehyde (1 \-cis- retinaldehyde) for use in photo-transduction by opsin proteins in photoreceptor cell outer segments, and (ii) converts RAL to retinol after photo-transduction. As RAL escapes the visual cycle, A2E precursors form reversibly in photoreceptor outer segments, which are ingested by neighboring RPE cells after diurnal shedding. The final and irreversible step in the biosynthesis of A2E takes place in the acidic environment of RPE cell lysosomes. As A2E accumulates in RPE cells, it gradually poisons them by multiple cytotoxic mechanisms including lysosomal failure. This leads to the accumulation of undigested cellular debris called lipofuscin, which contains A2E and can be detected clinically by FAF. As RPE cells deteriorate, they lose their ability to participate in the visual cycle and are unable to provide photoreceptors with other metabolic support required for normal retinal function (see Figure 1 ; Lamb TD, Pugh EN, Dark adaptation and the retinoid cycle of vision. Prog. Retinal and Eye Res. 2004;23 :307). As their metabolic support is withdrawn, photoreceptors fail to renew their shed outer segments and visual function is progressively lost. Reducing A2E formation will allow RPE cells to recover from A2E poisoning and resume their normal metabolic support of photoreceptor cells.
[0005] WO 2006/127945 discloses compounds and compositions that have been shown to reduce the formation of A2E, which as described above is the underlying etiology of macular degeneration including dry AMD and Stargardt's disease. These compounds are designed to inhibit A2E biosynthesis by reducing the amount of free RAL available for reaction with PE in photoreceptor outer segments, which is the first step in the A2E biosynthetic pathway. These compounds are lipophilic by design (i.e. the logarithm of their measured or calculated partition constant between water and rc-octanol [logP or clogP which are called logD or clogD respectively at pH 7.4 as used herein] is greater than 0), because their covalent reactions with RAL take place in the disc membranes of photoreceptor outer segments where A2E precursors form.
[0006] A different way to reduce A2E biosynthesis is to inhibit one or more proteins of the visual cycle, because when the visual cycle is inhibited, less RAL escapes the visual cycle and becomes available to react with PE and form A2E precursors. Chronic treatment with a visual cycle inhibitor has been shown to reduce A2E synthesis in mouse (Radu et al, Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci U S A. 2003; 100:4742). The clinical value of this treatment approach is limited by the fact that visual cycle inhibitors cause night blindness by lowering rod photoreceptor sensitivity, impair dark adaptation by slowing the dark adaptation rate, and cause retinoid toxicities by activating retinoic acid receptors (RAR) if the visual cycle inhibitor compound is a member of the retinoid class. Visual cycle inhibitors now in clinical development include fenretinide which is a retinoid compound, and ACU-4429 which reportedly is not a retinoid.
[0007] Other approaches to treating macular degeneration are based on neuroprotection mechanisms of action including but not limited to neurotrophic receptor agonists, anti-inflammatory compounds including complement cascade inhibitors, anti- apoptosis compounds, steroids and anti-oxidant compounds, and limiting the progression to wet AMD with VEGF receptor blockers which mitigate the effects of VEGF signaling by RPE cells that are in severe oxidative stress as a consequence of A2E toxicities.
Summary of the Invention
[0008] In therapeutic and prophylactic use, topical ocular administration minimizes systemic exposure compared to oral dosing. The present invention provides formulations and methods for topical ocular dosing of lipophilic compounds which treat macular degeneration (including dry AMD, GA secondary to dry AMD, wet AMD and Stargardt's disease) by reducing the formation of A2E and other naturally occurring bis-retinoids, by reacting covalently with free RAL that escapes the visual cycle and would otherwise form precursors of these compounds. The lipophilic compounds within the scope of this invention are further defined by having a logP or clogP (logD or clogD at pH =7.4) greater than 0.
Brief Description of the Figures
[0009] Figure 1 depicts the visual cycle.
[00010] Figure 2 depicts a time profile of the concentration of 14C-Compound A in ng/g of ocular tissue.
[0001 1] Figure 3 depicts effects of RA treatment on dark adaptation rate in the mouse after acute TO or IP administration of 13-czs-retinoic acid.
Detailed Description of the Invention
[00012] One embodiment of the present invention provides pharmaceutical compositions for treating macular degeneration (including dry AMD, GA secondary to dry AMD, wet AMD and Stargardt's disease). The root cause of macular degeneration is the cytotoxic accumulation in RPE cells of naturally occurring bis-retinoids including A2E. This accumulation can be lowered pharmacologically by limiting the amount of free RAL that escapes the visual cycle and otherwise reacts with PE to form their precursors. As the accumulation of these compounds is reduced pharmacologically, RPE cells can recover from cytotoxic damage and resume their metabolic support of photoreceptors which is essential for normal visual function. In publication WO 2006/127945, compounds are described which reduce A2E accumulation in this manner and are therefore useful in treating macular degeneration. The instant application incorporates by reference the subject matter of WO 2006/127945.
[00013] Lipophilic compounds which reduce A2E and thereby treat macular degeneration including dry AMD and Stargardt's disease by other means (e.g. by inhibiting the visual cycle) are also included within the scope of this invention. Such compounds include ACU-4429. All such compounds have a logP or clogP greater than 0.
[00014] In therapeutic or prophylactic use, topical ocular administration minimizes systemic exposure compared to oral dosing. However, most topical formulations have failed to deliver efficacious levels of drug to the retina which is the site of the mechanism of action. Surprisingly, applicants have found that by employing preparations containing a lipophilic active agent and a cyclodextrin, or chemically modified cyclodextrin including trimethyl-β- cyclodextrin, 2-hydroxyethyl-P-cyclodextrin, 2-hydroxypropyl-P-cyclodextrin, 3- hydroxypropyl-P-cyclodextrin, and β-cyclodextrin sulfobutylether sodium salt (or potassium salt), efficacious levels of the lipophilic active agent are delivered to the back of the eye and specifically to the RPE and retina. Pharmaceutical compositions of a lipophilic active agent and an oligomeric or a polymeric carrier such as a cyclodextrin or chemically modified cyclodextrin including trimethyl-P-cyclodextrin, 2-hydroxyethyl-p-cyclodextrin, 2- hydroxypropyl-P-cyclodextrin, 3-hydroxypropyl-P-cyclodextrin, and β-cyclodextrin sulfobutylether sodium salt (or potassium salt) are useful for the treatment of macular degeneration (including dry age-related macular degeneration, GA secondary to dry AMD, wet AMD and Stargardt's disease).
[00015] One exemplification of the present invention is represented by a topical ophthalmic composition containing an active lipophilic compound and an oligomeric or a polymeric carrier such as a cyclodextrin, or a chemically modified cyclodextrin including trimethyl-p-cyclodextrin, 2-hydroxyethyl- -cyclodextrin, 2-hydroxypropyl-P-cyclodextrin, 3- hydroxypropyl-P-cyclodextrin, and β-cyclodextrin sulfobutylether sodium salt (or potassium salt) in an aqueous solution or a gel dispersion. Such active lipophilic compounds include those that reduce A2E by reacting covalently with RAL, e.g. the compounds of WO 2006/127945. Illustrative of such compounds are those described in WO 2006/127945 the contents of which application are herein incorporated by reference. Exemplifying the compounds which may be employed in the instant invention are the compounds of formula
Figure imgf000007_0001
and pharmaceutically acceptable salts thereof, wherein X, Y, and Z are each, independently, N, CH, C with the NH2 attached, or absent, such that one of X, Y, and Z is N; p is 0, 1, 2, or 3,
B is a halogen atom, hydroxyl, carbamoyl, amino, or aryl, A is
Figure imgf000007_0002
s D is unbranched lower alkyl. Specifically, compound A of paragraph (00027) of WO 2006/ 127945 and pharmaceutically acceptable salts thereof may be employed in the instant invention.
Figure imgf000007_0003
[00016] Further illustrating the useful compounds herein are the compounds of formula Ilia:
Figure imgf000007_0004
and pharmaceutically acceptable salts thereof, wherein L is a single bond or CH2; X, Y, and Z are each, independently, N, NH, O, S, CB, CH, or absent, such that one of X, Y, and Z is N or
D
D -
NH; p is 0, 1 , 2, or 3;B is a halogen atom, hydroxyl, carbamoyl, aryl or amino;A is OH ; and D is unbranched lower alkyl; and
[00017] Specifically, compounds B and C of paragraph (00046) of WO 2006/127945, and pharmaceutically acceptable salts thereof may be employed in the instant invention.
Figure imgf000007_0005
B)
Figure imgf000008_0001
[00018] The amount of active agent in the composition will vary dependent on the intrinsic activity of the compound. However, for compounds of formula la and formula Ilia the amount will generally be from 0.01-1.0% weight/volume and more particularly 0.1% to 0.5% weight/volume. In each case a compound as described above may be used or a pharmaceutically acceptable salt of said compound. The term lipophilic compound is meant to include the compound and its pharmaceutically acceptable salts. A pharmaceutically acceptable salt herein means a salt that is capable of being topically delivered to the eye of a patient. The carrier in the composition is an oligomeric or a polymeric carrier such as a cyclodextrin including trimethyl-p-cyclodextrin, 2-hydroxyethyl^-cyclodextrin, 2- hydroxypropyl- -cyclodextrin, 3-hydroxypropyl-P-cyclodextrin, and β-cyclodextrin sulfobutylether sodium salt (or potassium salt). Exemplifying an oligomeric or a polymeric carrier is β-cyclodextrin sulfobutylether sodium salt. The amount of β-cyclodextrin sulfobutylether sodium salt in the aqueous preparation may range from about 0.01% to 30% weight/volume. In one illustration the concentration of β-cyclodextrin sulfobutylether sodium salt is 5-25% weight/volume. Further illustrating the concentration of β-cyclodextrin sulfobutylether sodium salt is 9.5-20%) weight/volume. In one exemplification the concentration of β-cyclodextrin sulfobutylether is 9.5% weight/volume.
[00019] It should be noted that, although the compositions are further illustrated with β-cyclodextrin sulfobutylether, each lipophilic agent may be formulated with each of the excipients. The composition may contain saline and be buffered with for example a phosphate buffer so that the pH of the composition is brought to a pH range of 5.5-8.5 or more particularly a pH of 6.5-7.5. A preservative may optionally be included in the composition. Such preservatives can include both chemical stabilizers and antiseptics. Compounds such as Compounds A are stable under the conditions of use, however other compounds may require the use of other excipients such as anti-oxidants.
[00020] A second embodiment of the invention is directed to a method of treating macular degeneration (including dry age-related macular degeneration, GA secondary to dry AMD, wet AMD and Stargardt's disease), by administering a topical formulation of an active lipophilic compound and a carrier to the eye(s) of a patient. In another embodiment, the present invention provides a topical ophthalmic composition for use in treating macular degeneration wherein said composition comprises an active lipophilic compound and a carrier or a pharmaceutically acceptable salt thereof in an aqueous solution. Exemplifying the carrier is β-cyclodextrin sulfobutylether or a pharmaceutically acceptable sat thereof. The active lipophilic compound in each of these embodiments includes those that reduce A2E by reacting with RAL, e.g. the compounds of WO 2006/127945. Examples of such compounds are those described in WO 2006/127945. Exemplifying such compounds are Compounds A, B and C. Lipophilic Compounds which function by other mechanisms such as ACU-4429 are also included. The term lipophilic compound is meant to include both the compound and its pharmaceutically acceptable salts. The excipient in the formulation is oligomeric or polymeric such as a cyclodextrin or a chemically modified cyclodextrin, more particularly including β-cyclodextrin sulfobutylether sodium salt (or potassium salt). It should be noted that, although particularly illustrated with β-cyclodextrin sulfobutylether, the method may be practiced with each lipophilic compound formulated with each excipient. The formulation may be buffered to a pH range of 5.5-8.5 or more particularly a pH of 6.5-7.5. The buffer may be a phosphate buffer. The formulation may be applied as an aqueous solution or a gel dispersion and the solution may be a saline solution. The accumulation of lipofuscin occurs in RPE cells in the back of the eye. Applicants have determined experimentally in animals that the use of topical compositions as described herein deliver pharmacologically active levels of lipophilic active drug safely to the back of the eye after topical ocular administration and are therefore useful in the treatment of macular degeneration (including dry age-related macular degeneration, GA secondary to dry AMD, wet AMD and Stargardt's disease). Efficacious levels are defined as those that reduce A2E accumulation significantly in animal studies.
Preparation of Compositions of The Invention
[00021] Formulations of a lipophilic active agent and an oligomeric or a polymeric carrier are prepared by stirring an aqueous suspension or solution of a polymeric carrier such as a cyclodextrin, or chemically modified cyclodextrin including trimethyl- -cyclodextrin, 2- hydroxyethyl- -cyclodextrin, 2-hydroxypropyl-P-cyclodextrin, 3-hydroxypropyl-P- cyclodextrin, and β-cyclodextrin sulfobutylether sodium (or potassium) salt with water, saline or phosphate-buffered saline at a temperature from 20°C to 50°C, but preferably at ambient temperature, for 0.1 -24 hr, depending on the polymeric carrier. The lipophilic active agent is added as a solid or neat liquid to the thus formed aqueous suspension or solution of polymeric carrier, and the resulting mixture is stirred at a temperature from 20°C to 50°C, but preferably at ambient temperature, for 0.1-24 hr, but typically from 0.5-2 hr, depending on the lipophilic active agent. The thus formed formulation of a lipophilic active agent and an oligomeric or a polymeric carrier may then be treated with an aqueous solution of an inorganic or organic acid or an inorganic or organic base to adjust the pH of the solution as desired. To the formulation may also be added preservatives, including both chemical stabilizers and antiseptics.
Example 1 -Preparation of a 0.1% w/v aqueous formulation of Compound A with 9.5% w/v β-cyclodextrin sulfobutylether.
[00022] The preparation was carried out in a 1000 ml beaker equipped with a stirring bar for mixing. Approximately 60% of the targeted weight of sterile water was added to the beaker. Stirring was adjusted so as not to incorporate air. Anhydrous dibasic sodium phosphate (0.83% of the total batch weight) and sodium phosphate monobasic monohydrate (0.017% of the total batch weight) was added to the vessel and mixed until dissolved, β- cyclodextrin sulfobutylether (9.5% of the total batch weight) was slowly added to the beaker and the solution mixed until dissolved. Compound A (0.1% of the total batch weight) was slowly added and mixed until dissolved. A sample was extracted and the pH measured. If the pH was not in the range 7.3±0.05 , adjustment was made with IN aqueous NaOH or IN aqueous HC1. The batch weight was measured and the amount of sterile water needed to bring to final batch weight was determined and added.
Results of Applying Formulations to the Eyes of Mice and Rabbits.
1) Measurement of levels of 14C-Compound A in the posterior eyecup of mice.
[00023] The target tissue, for the biological activity of compounds which reversibly react with RAL, e.g. Compounds A, B and C, is the outer segment of retinal photoreceptor cells. To demonstrate that topical optical (TO) administration of Compound A delivers therapeutically useful amounts of, for example, Compound A to the retina, C57BL/6 mice, the parent strain of abcr -I- mice (knockout mouse), were treated intraperitoneal ly (IP) with 14C-Compound A at 10 mg/kg ("efficacious dose"), specifically a dose that when repeated daily for 56 days reduced A2E formation by 71% (p < 0.01) in the abcr -I- mouse. At certain timepoints after topical ocular dosing, the eyes of the mice were enucleated and the posterior eyecup was dissected, extracted and analyzed by liquid scintillation chromatography (LSC) for ,4C-Compound A. Thirty minutes after IP treatment with 14C-Compound A, the Cmax amount of 14C-Compound A in the posterior eyecup (i.e. the peak concentration at time Tma ) was 14.36 pg/g. Fifteen minutes after TO treatment with a single 5 pL eyedrop containing 25 pg (0.5% weight/volume) 14C-Compound A in a composition containing 20% weight/volume β-cyclodextrin sulfobutylether sodium salt in phosphate-buffered saline, the equivalent amount of 14C-Compound A in the posterior eyecup was 13.12 pg/g, which is 90% of the Cmax value measured in the same ocular tissue after systemic treatment at an efficacious dose.
2) Ocular levels of 14C-Compound A in the retina and RPE of rabbits. [00024] Dutch belted rabbits were dosed TO with a single 40 μΐ^ eyedrop containing either 0.50%, 0.15% or 0.05% weight/volume 14C-Compound A in 20%, 6% or 2% weight/volume, respectively, β-cyclodextrin sulfobutylether sodium salt in phosphate- buffered saline (Table 1). At different times after dosing the eyes of the rabbits were enucleated, dissected and the amount of 14C-Compound A in the retina and RPE together was measured by LSC. Each value represents the mean value from 6 eyes. Significant amounts of 14C-Compound A were found in rabbit retina/RPE within one hour of TO dosing as shown in Table 1.
3) Topical Ocular Dosing with 14C-Compound A in Cynomolgus Macaques.
[00025] The pharmacokinetics (PK) of Compound A in four intraocular regions of Cynomolgus Macaques was measured after topical dosing of 40 μΕ per eye of 0.50% weight/volume 1 C-Compound A in β-cyclodextrin sulfobutylether sodium salt in phosphate- buffered saline. Sampling of intraocular regions (vitreous humor, retina+RPE, anterior eyecup, and posterior eyecup) and blood for PK evaluation was conducted at 0.25, 0.5, 1, 3, 6 and 9 hours post dose. Figure 2 shows the time course of 14C-Compound A concentration expressed in nanograms (ng ) per gram (g) of ocular tissue.
Table 1. 14C-Compound A levels in rabbit retina and RPE after acute TO dosing in β- cyclodextrin sulfobutylether sodium salt.
Figure imgf000012_0001
1 β-cyclodextrin sulfobutylether sodium salt; w/v = weight/volume.
4) Functional biological activity in mice.
[00026] The biological activity in the retina of some drugs within the scope of the invention such as Compounds A, B and C cannot be measured non-invasively after topical ocular application because these drugs, e.g. Compounds A, B and C, do not alter the normal function of the retina. For example Compound A does not inhibit the visual cycle nor does it slow the rate of dark adaptation (DA), changes which can be measured by electroretinography (ERG) within minutes after equivalent treatment with a visual cycle inhibitor. The protocol for measuring DA rates by ERG is based on the kinetics of functional visual recovery from photo-bleaching of visual pigment by brief exposure to extremely bright light. Like Compounds A, B and C, retinoids are lipophilic compounds as defined above. As such, retinoids can be used to demonstrate that a small lipophilic compound in a composition containing β-cyclodextrin sulfobutylether sodium salt exhibits biological activity in the retina minutes to hours after topical application to the front of the eye.
[00027] A retinoid useful for this purpose is 13-m-retinoic acid (RA, also known as isotretinoin). Mice treated IP at 20 mg/kg with RA show visual cycle inhibition (Figure 3). Independent studies demonstrate that the visual cycle inhibition decreases A2E synthesis (Radu RA, Mata NL, Nusinowitz S, Liu X, Sieving PA, Travis GH. Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci 2003;100:4742). However, mice treated TO with one or two 30 eyedrops of a composition containing 0.2% weight/volume RA and 20% weight/volume β-cyclodextrin sulfobutylether sodium salt in phosphate-buffered saline showed a dose-responsive inhibition of DA similar to that observed after IP dosing (Figure 3)·

Claims

What is claimed is:
1. A topical ophthalmic composition comprising a lipophilic compound selected from the group consisting of Compound A, Compound B and Compound C and a carrier selected from β-cyclodextrin sulfobutylether or a pharmaceutically acceptable salt thereof in an aqueous solution.
2. The composition of claim 1 wherein the lipophilic compound is Compound A or a pharmaceutically acceptable salt thereof.
3. The composition of claim 2 wherein the carrier is β-cyclodextrin sulfobutylether sodium salt.
4. The composition of claim 3 wherein the solution is an aqueous saline solution phosphate buffered to a pH of 6.5-7.5.
5. The composition of claim 4 wherein the concentration of β-cyclodextrin sulfobutylether sodium salt is 9.5 - 20 % w/v.
6. The composition of claim 5 wherein the concentration of β-cyclodextrin sulfobutylether sodium salt is 9.5 % w/v.
7. A method for treating macular degeneration comprising administering a topical ophthalmic composition to the eye(s) of a patient, wherein said topical composition comprises a lipophilic compound selected from the group consisting of Compound A, Compound B and Compound C and a carrier selected from β-cyclodextrin sulfobutylether or a pharmaceutically acceptable salt thereof in an aqueous solution.
8. The method of claim 7 wherein the lipophilic compound is Compound A or a pharmaceutically acceptable salt thereof.
9. The method of claim 8 wherein the carrier is β-cyclodextrin sulfobutylether sodium salt.
10. The method of claim 9 wherein the solution is an aqueous saline solution phosphate buffered to a pH of 6.5-7.5.
1 1. The method of claim 10 wherein the concentration of β-cyclodextrin sulfobutylether sodium salt is 9.5 - 20% w/v.
12. The method of claim 1 1 wherein the concentration of β-cyclodextrin sulfobutylether is 9.5% w/v.
13. The method of claim 12 wherein the form of macular degeneration being treated is dry AMD.
14. The method of claim 12 wherein the form of macular degeneration being treated is geographic atrophy secondary to dry AMD.
15. The method of claim 12 wherein the form of macular degeneration being treated is wet AMD.
16. The method of claim 12 wherein the form of macular degeneration being treated is Stargardt's disease.
PCT/US2010/059719 2009-12-11 2010-12-09 Compositions and methods for the treatment of macular degeneration WO2011072141A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/514,769 US9814701B2 (en) 2009-12-11 2010-12-09 Compositions and methods for the treatment of macular degeneration
JP2012543284A JP5885670B2 (en) 2009-12-11 2010-12-09 Compositions and methods for the treatment of macular degeneration
CA2782015A CA2782015C (en) 2009-12-11 2010-12-09 Topical ophthalmic compositions and methods for the treatment of macular degeneration
US15/782,470 US20180092882A1 (en) 2009-12-11 2017-10-12 Compositions and methods for the treatment of macular degeneration
US18/241,598 US12097188B2 (en) 2009-12-11 2023-09-01 Compositions and methods for the treatment of macular degeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28574509P 2009-12-11 2009-12-11
US61/285,745 2009-12-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/514,769 A-371-Of-International US9814701B2 (en) 2009-12-11 2010-12-09 Compositions and methods for the treatment of macular degeneration
US15/782,470 Continuation US20180092882A1 (en) 2009-12-11 2017-10-12 Compositions and methods for the treatment of macular degeneration

Publications (1)

Publication Number Publication Date
WO2011072141A1 true WO2011072141A1 (en) 2011-06-16

Family

ID=44145918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/059719 WO2011072141A1 (en) 2009-12-11 2010-12-09 Compositions and methods for the treatment of macular degeneration

Country Status (4)

Country Link
US (3) US9814701B2 (en)
JP (4) JP5885670B2 (en)
CA (1) CA2782015C (en)
WO (1) WO2011072141A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014116836A2 (en) 2013-01-23 2014-07-31 Aldexa Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US20150344447A1 (en) * 2013-01-25 2015-12-03 Aldeyra Therapeutics, Inc. Novel traps in the treatment of macular degeneration
US9364471B2 (en) 2005-05-26 2016-06-14 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US10414732B2 (en) 2017-03-16 2019-09-17 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US10426790B2 (en) 2016-02-28 2019-10-01 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
EP3454858A4 (en) * 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US11197821B2 (en) 2018-09-25 2021-12-14 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
US11312692B1 (en) 2018-08-06 2022-04-26 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2022092896A1 (en) * 2020-10-29 2022-05-05 주식회사 피노바이오 Pharmaceutical composition for administration as ophthalmic drop to patient requiring optic nerve protection
EP3934660A4 (en) * 2019-03-05 2022-11-23 Cornell University Compositions of matter with activity to remove lipofuscin from retinal cells
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
US12029735B2 (en) 2019-05-02 2024-07-09 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12064516B2 (en) 2020-05-13 2024-08-20 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
US12097188B2 (en) 2009-12-11 2024-09-24 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
US12128013B2 (en) 2023-08-22 2024-10-29 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201504859YA (en) 2012-12-20 2015-07-30 Aldeyra Therapeutics Inc Peri-carbinols

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
WO2006127945A1 (en) * 2005-05-26 2006-11-30 Neuron Systems Compositions and methods of treating retinal disease

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
SU50906A1 (en) 1935-12-20 1936-11-30 А.И. Бурляев Spindle for spinning machines
GB1435721A (en) 1972-05-18 1976-05-12 Lilly Industries Ltd Benzoxazole derivatives
SU509046A1 (en) 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Derivatives of 2-carbethoxy-3-aminoindole having antiinflammatory effect and process for preparing same
JPS6192592A (en) 1984-10-12 1986-05-10 Norin Suisansyo Shokuhin Sogo Kenkyusho Production of branched cyclodextrin
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
US5032392A (en) 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
NZ225045A (en) 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0506949A1 (en) 1990-10-22 1992-10-07 BAUSCH &amp; LOMB INCORPORATED Method and composition for cleaning contact lenses
CA2054339C (en) 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
JP2746832B2 (en) 1993-05-14 1998-05-06 大鵬薬品工業株式会社 Ocular topical antiallergic agent
GB9318431D0 (en) 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
US5767109A (en) 1993-10-20 1998-06-16 Sanchez; Robert A. Complexing urushiols
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
JP3297969B2 (en) 1994-12-26 2002-07-02 ライオン株式会社 Eye drops
JPH08175985A (en) 1994-12-26 1996-07-09 Lion Corp Ophthalmic solution
US5597823A (en) 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
FR2742053B1 (en) 1995-12-06 1998-03-06 Chauvin Lab Sa PHARMACEUTICAL COMPOSITIONS BASED ON MEQUITAZINE
JP3736916B2 (en) 1996-02-19 2006-01-18 株式会社サンコンタクトレンズ Disinfecting composition for hydrous soft contact lens and its use
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
BR9711110A (en) 1996-08-01 1999-08-17 Dow Agrosciences Lic 4-substituted quinoline derivatives having fungicidal activity
ES2191183T3 (en) 1996-08-06 2003-09-01 Pfizer 6,6- OR 6,7-BICYCLE DERIVATIVES CONTAINING REPLACED OR REQUIRED PIRIMIDO.
ATE336485T1 (en) 1997-05-02 2006-09-15 Schering Ag SUBSTITUTED HETEROCYCLES AND THEIR USE IN MEDICINAL PRODUCTS
JPH10306022A (en) 1997-05-06 1998-11-17 Lion Corp Ophthalmic solution
GB2327672A (en) 1997-07-23 1999-02-03 Merck & Co Inc 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine
EP1012151B1 (en) 1997-09-02 2002-08-07 Bristol-Myers Squibb Pharma Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
HUP0102612A2 (en) 1998-03-12 2001-11-28 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
JP3568108B2 (en) 1999-07-28 2004-09-22 松下電器産業株式会社 Method for transmitting location information of digital map and apparatus for implementing the method
US6515010B1 (en) 1999-11-15 2003-02-04 Smithkline Beecham Corporation Carvedilol methanesulfonate
AU1735001A (en) 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
EP1248869A2 (en) 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
JP2001318350A (en) 2000-05-11 2001-11-16 Lion Corp Solution for contact lens
JP4748289B2 (en) 2000-06-23 2011-08-17 ライオン株式会社 Eye drops, ophthalmic composition, and adsorption suppression method
FR2827599A1 (en) 2001-07-20 2003-01-24 Neuro3D Treating central nervous system disorders, e.g. anxiety, depression, schizophrenia or pain, using new or known 2-substituted quinoline or quinoxaline derivatives having xanthenuric acid modulating action
UA83620C2 (en) 2001-12-05 2008-08-11 Уайт Substituted benzoxazoles and analogues as estrogenic agents
CA2416228C (en) * 2002-01-15 2010-07-13 Olsonet Communications Corporation Communication nodes for use with a wireless ad-hoc communication network
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040198828A1 (en) 2003-01-17 2004-10-07 Abelson Mark B. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
CA2518655C (en) 2003-03-14 2015-06-09 University Of Washington Retinoid replacements and opsin agonists and methods for the use thereof
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
EP2289488A3 (en) * 2003-04-18 2011-03-30 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
JP2005132834A (en) 2003-10-09 2005-05-26 Kyowa Hakko Kogyo Co Ltd Quinoline derivative
KR101163800B1 (en) 2003-10-15 2012-07-09 산텐 세이야꾸 가부시키가이샤 Novel indazole derivative
BRPI0415863A (en) 2003-10-27 2007-01-09 Astellas Pharma Inc pyrazine derivatives and their pharmaceutical uses
US20050130906A1 (en) 2003-11-20 2005-06-16 Matier William L. Amelioration of macular degeneration and other ophthalmic diseases
JP2005187407A (en) 2003-12-25 2005-07-14 Lion Corp Ophthalmic composition for allergic eye disease
MXPA06008780A (en) 2004-02-17 2007-02-16 Harvard College Management of ophthalmologic disorders, including macular degeneration.
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
JP2006008568A (en) 2004-06-24 2006-01-12 Cyclochem:Kk IgE ANTIBODY-SUPPRESSING AGENT AND FOOD
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
FR2875409B1 (en) 2004-09-17 2010-05-07 Sanofi Aventis PHARMACEUTICAL COMPOSITION COMPRISING A SOLID POLYMERIC MATRIX DISPERSION COMPRISING A CONTINUOUS PHASE OF POLYDEXTROSE AND A CONTINUOUS PHASE OF A POLYMER OTHER THAN POLYDEXTROSE
US20070287716A1 (en) 2004-10-28 2007-12-13 Hu Essa H Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors
US20100160304A1 (en) 2005-01-19 2010-06-24 Dainippon Sumitomo Pharma Co., Ltd Aromatic sulfone compound as aldosterone receptor modulator
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CN1830964B (en) 2005-03-11 2011-06-15 中国科学院上海药物研究所 4-Substituting anilino-3-nitroquinoline compounds, prepn. method and use thereof
WO2006122183A2 (en) 2005-05-10 2006-11-16 Cytophil, Inc. Injectable hydrogels and methods of making and using same
CN101351199B (en) 2005-12-27 2013-01-02 狮王株式会社 Composition for soft contact lens and adsorption suppressing method
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20070297981A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
JP4466875B2 (en) 2006-04-05 2010-05-26 ライオン株式会社 Eye drops for soft contact lenses
US20100144693A1 (en) 2006-04-14 2010-06-10 Prana Biotechnology Limited Method of treatment of age-related macular degeneration (amd)
JP5194218B2 (en) 2006-06-05 2013-05-08 株式会社メニコンネクト Preservation method of hydrous contact lens and hydrous contact lens preserved by the preservation method
EP2079699A1 (en) 2006-07-25 2009-07-22 Envivo Pharmaceuticals, Inc. Quinoline derivatives
MX2009001770A (en) 2006-08-14 2009-02-25 Schering Corp Salts of 5 - ( l ( s ) -amino - 2 - hydroxyethyl ) -n- [ ( 2, 4 -difluorophenyl) -methyl] - 2 - [ 8 -methoxy - 2 - (trifluoromethyl) - 5 - quinoline] - 4 - oxazolecarboxamide.
KR20140114887A (en) 2006-08-31 2014-09-29 앱탈리스 파마테크, 인코포레이티드 Drug delivery systems comprising solid solutions of weakly basic drugs
TW200823187A (en) 2006-10-24 2008-06-01 Wyeth Corp Benzodioxane derivatives and uses thereof
US8158609B1 (en) 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
US20080241256A1 (en) 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
US8490764B2 (en) 2007-05-30 2013-07-23 Margaret Simester Portable storage and changing station
TW201242961A (en) 2007-06-20 2012-11-01 Ironwood Pharmaceuticals Inc FAAH inhibitors
MX354184B (en) 2007-10-05 2018-02-16 Acucela Inc Alkoxy compounds for disease treatment.
EP2252276B1 (en) 2008-02-11 2019-03-27 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
BRPI0917634A2 (en) 2008-08-12 2015-11-17 Sirtris Pharmaceuticals Inc benzoxazoles, benzthiazoles and related analogues as sirtuin modulators
EA201100654A1 (en) 2008-10-22 2012-01-30 Акусела, Инк. CONNECTIONS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS
AU2009315735B2 (en) 2008-11-11 2013-01-10 Novartis Ag Salts of fingolimod
CA2754996A1 (en) 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
WO2010133672A1 (en) 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use
JP2012528889A (en) 2009-06-05 2012-11-15 アーシエックス セラピューティックス， インコーポレイテッド Fluticasone ophthalmic formulation and method of use
US20100331315A1 (en) 2009-06-18 2010-12-30 Mustapha Haddach Rhodanines and related heterocycles as kinase inhibitors
WO2011008202A1 (en) 2009-07-15 2011-01-20 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
TWI492769B (en) 2009-09-23 2015-07-21 Alcon Res Ltd Injectable aqueous ophthalmic composition and method of use therefor
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
JPWO2011078204A1 (en) 2009-12-24 2013-05-09 浜理薬品工業株式会社 Preventive or therapeutic agent for hyperlipidemia, and anti-fatigue agent
CN105726531A (en) 2010-02-26 2016-07-06 泽农医药公司 Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US8575221B2 (en) 2010-03-17 2013-11-05 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
JP2011203665A (en) 2010-03-26 2011-10-13 Ophtecs Corp Defogging product and defogging method for contact lens
MX2013002422A (en) 2010-09-01 2013-05-17 Arena Pharm Inc Salts of lorcaserin with optically active acids.
US9364430B2 (en) 2010-10-29 2016-06-14 Relmada Therapeutics, Inc. Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
MX346387B (en) 2011-01-12 2017-03-02 Ventirx Pharmaceuticals Inc Substituted benzoazepines as toll-like receptor modulators.
US10463687B2 (en) 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
CN103442735B (en) 2011-01-31 2016-11-09 特米拉公司 Active principle for undesirable medical condition in mitigation technique field
TWI544922B (en) 2011-05-19 2016-08-11 愛爾康研究有限公司 High concentration olopatadine ophthalmic composition
US20140349943A1 (en) 2011-10-13 2014-11-27 Thomas Gadek Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions
US20130190500A1 (en) 2011-12-12 2013-07-25 Neuron Systems, Inc. Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene
US9817701B2 (en) 2011-12-12 2017-11-14 International Business Machines Corporation Threshold computing in a distributed computing system
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
GB201200192D0 (en) 2012-01-06 2012-02-22 Rosemont Pharmaceuticals Ltd Methotrexate composition
EP2879683B1 (en) 2012-08-01 2020-01-22 Lewis and Clark Pharmaceuticals, Inc. N-alkyl-alkynyladenosine-5-uronamide compounds as agonists of a2a receptor
SG11201503637SA (en) 2012-11-08 2015-06-29 Clearside Biomedical Inc Methods and devices for the treatment of ocular diseases in human subjects
SG11201504859YA (en) 2012-12-20 2015-07-30 Aldeyra Therapeutics Inc Peri-carbinols
SG11201505587YA (en) 2013-01-23 2015-08-28 Aldeyra Therapeutics Inc Toxic aldehyde related diseases and treatment
BR112015017246B1 (en) 2013-01-23 2022-11-29 Semnur Pharmaceuticals, Inc INJECTABLE AQUEOUS PHARMACEUTICAL COMPOSITION, ITS USE AND SYRINGE
WO2014116593A1 (en) 2013-01-25 2014-07-31 Aldexa Therapeutics, Inc. Novel traps in the treatment of macular degeneration
TWI643853B (en) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES
US9713330B1 (en) 2013-03-15 2017-07-25 Deuteria Agrochemicals, Llc Deuterium-enriched aldehydes
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
EP3151818A4 (en) 2014-06-04 2018-05-30 Case Western Reserve University Compositions and methods of treating diabetic retinopathy
WO2015198350A1 (en) 2014-06-25 2015-12-30 Synergia Bio Sciences Private Limited A pharmaceutical oil-in-water nano-emulsion
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
NO2721710T3 (en) 2014-08-21 2018-03-31
CN106794986A (en) 2014-09-02 2017-05-31 布平德尔·辛格 Deuterate or non-deuterate molecule and pharmaceutical preparation
TW201628622A (en) 2014-11-17 2016-08-16 製藥公司 TLR inhibitor and BRUTON'S tyrosine kinase inhibitor combinations
WO2016085939A2 (en) 2014-11-24 2016-06-02 Case Western Reserve University Compounds and methods of treating ocular disorders
US9953187B2 (en) 2014-11-25 2018-04-24 Honeywell International Inc. System and method of contextual adjustment of video fidelity to protect privacy
EP4119559A1 (en) 2015-04-15 2023-01-18 BeiGene, Ltd. Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
MX2018002157A (en) 2015-08-21 2018-06-08 Aldeyra Therapeutics Inc Aldehyde conjugates and uses thereof.
EP4400106A1 (en) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
GB201522441D0 (en) 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
AU2017224249A1 (en) 2016-02-28 2018-09-13 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US11865113B2 (en) 2016-06-06 2024-01-09 Lipidio Pharmaceuticals Inc. Methods of treating a patient afflicted with non-alcoholic steatohepatitis (NASH)
AU2017317529A1 (en) 2016-08-22 2019-02-21 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and methods of use thereof
CA3032521A1 (en) 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and uses thereof
US11510931B2 (en) 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
WO2018067860A1 (en) 2016-10-05 2018-04-12 Mitobridge, Inc. Crystalline and salt forms of ppar agonist compounds
US20180098937A1 (en) 2016-10-12 2018-04-12 Ps Therapies Ltd Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
GB2556082A (en) 2016-11-18 2018-05-23 Warneford Healthcare Ltd Ophthalmic composition
ES2968462T3 (en) 2017-03-16 2024-05-09 Aldeyra Therapeutics Inc Polymorphic salt of 6-chloro-3-amino-2(2-hydroxyprolyl) quinoline and uses thereof
US10664688B2 (en) 2017-09-20 2020-05-26 Google Llc Systems and methods of detecting and responding to a visitor to a smart home environment
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
MX2020006207A (en) 2017-12-14 2020-08-27 Lutron Tech Co Llc Privacy mode for a wireless audio device.
WO2020018498A1 (en) 2018-07-16 2020-01-23 Aldeyra Therapeutics, Inc. Cyclodextrin formulations
US20200038392A1 (en) 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US10915995B2 (en) 2018-09-24 2021-02-09 Movidius Ltd. Methods and apparatus to generate masked images based on selective privacy and/or location tracking
EP3856478A4 (en) 2018-09-25 2022-06-08 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
WO2020072621A1 (en) 2018-10-02 2020-04-09 Aldeyra Therapeutics, Inc. Contact lens solutions and kits
WO2020118045A1 (en) 2018-12-05 2020-06-11 Aldeyra Therapeutics, Inc. Injectable formulations
JP2022526917A (en) 2019-03-26 2022-05-27 アルデイラ セラピューティクス， インコーポレイテッド Ophthalmic preparations and their use
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP2022530967A (en) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド Polymorphic compounds and their use
WO2021051003A1 (en) 2019-09-13 2021-03-18 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
WO2021195211A1 (en) 2020-03-24 2021-09-30 Aldeyra Therapeutics, Inc. Quinoline compounds for treating respiratory disorders and viral infections
JP2023522000A (en) 2020-04-13 2023-05-26 アルデイラ セラピューティクス， インコーポレイテッド Quinoline compounds for treating lung, liver and kidney diseases, disorders or conditions
JP2023526016A (en) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド Pharmaceutical formulations and their uses
WO2021248031A1 (en) 2020-06-04 2021-12-09 Aldeyra Therapeutics, Inc. Dry eye disease biomarkers and their use for treatment
CN112541870A (en) 2020-12-07 2021-03-23 北京大米科技有限公司 Video processing method and device, readable storage medium and electronic equipment
WO2022150580A1 (en) 2021-01-07 2022-07-14 Aldeyra Therapeutics, Inc. Treatment of dry eye disease
US20220211691A1 (en) 2021-01-07 2022-07-07 Aldeyra Therapeutics, Inc. Treatment of dry eye disease
CN112800947A (en) 2021-01-27 2021-05-14 上海电气集团股份有限公司 Video monitoring method, system, electronic equipment and storage medium
JP2024525430A (en) 2021-07-02 2024-07-12 アルデイラ セラピューティクス， インコーポレイテッド Heterocyclic compounds for trapping aldehydes and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
WO2006127945A1 (en) * 2005-05-26 2006-11-30 Neuron Systems Compositions and methods of treating retinal disease

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11724987B2 (en) 2005-05-26 2023-08-15 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US9364471B2 (en) 2005-05-26 2016-06-14 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US10913722B2 (en) 2005-05-26 2021-02-09 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US12097188B2 (en) 2009-12-11 2024-09-24 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
CN111135171A (en) * 2013-01-23 2020-05-12 奥尔德拉医疗公司 Diseases and treatments associated with toxic aldehydes
US10588874B2 (en) 2013-01-23 2020-03-17 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
CN111135171B (en) * 2013-01-23 2023-09-08 奥尔德拉医疗公司 Diseases and treatments associated with toxic aldehydes
US11771664B2 (en) 2013-01-23 2023-10-03 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
WO2014116836A2 (en) 2013-01-23 2014-07-31 Aldexa Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US11007157B2 (en) 2013-01-23 2021-05-18 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US10543181B2 (en) 2013-01-23 2020-01-28 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US10213395B2 (en) 2013-01-23 2019-02-26 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US11701331B2 (en) 2013-01-23 2023-07-18 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US10111862B2 (en) * 2013-01-25 2018-10-30 Aldeyra Therapeutics, Inc. Traps in the treatment of macular degeneration
US20190125729A1 (en) * 2013-01-25 2019-05-02 Aldeyra Therapeutics, Inc. Novel traps in the treatment of macular degeneration
US20150344447A1 (en) * 2013-01-25 2015-12-03 Aldeyra Therapeutics, Inc. Novel traps in the treatment of macular degeneration
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
EP4400106A1 (en) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US10426790B2 (en) 2016-02-28 2019-10-01 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
EP3454858A4 (en) * 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US10414732B2 (en) 2017-03-16 2019-09-17 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11583529B2 (en) 2017-10-10 2023-02-21 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11312692B1 (en) 2018-08-06 2022-04-26 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11197821B2 (en) 2018-09-25 2021-12-14 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
JP7505786B2 (en) 2018-09-25 2024-06-25 アルデイラ セラピューティクス， インコーポレイテッド Formulations for treating dry eye disease
EP3934660A4 (en) * 2019-03-05 2022-11-23 Cornell University Compositions of matter with activity to remove lipofuscin from retinal cells
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
US12029735B2 (en) 2019-05-02 2024-07-09 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
US12064516B2 (en) 2020-05-13 2024-08-20 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
WO2022092896A1 (en) * 2020-10-29 2022-05-05 주식회사 피노바이오 Pharmaceutical composition for administration as ophthalmic drop to patient requiring optic nerve protection
US12128013B2 (en) 2023-08-22 2024-10-29 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment

Also Published As

Publication number Publication date
JP2016130266A (en) 2016-07-21
US20240148700A1 (en) 2024-05-09
JP6378242B2 (en) 2018-08-22
JP2015057437A (en) 2015-03-26
US12097188B2 (en) 2024-09-24
JP6063916B2 (en) 2017-01-18
JP2017052799A (en) 2017-03-16
CA2782015C (en) 2020-08-25
JP2013513612A (en) 2013-04-22
JP5885670B2 (en) 2016-03-15
US20120302601A1 (en) 2012-11-29
US9814701B2 (en) 2017-11-14
US20180092882A1 (en) 2018-04-05
CA2782015A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
US12097188B2 (en) Compositions and methods for the treatment of macular degeneration
CN107362157B (en) Ophthalmic pharmaceutical composition for use in medicine and veterinary medicine
JP5315252B2 (en) Gels useful for transporting ophthalmic drugs
KR101396731B1 (en) PROTECTIVE AGENT FOR RETINAL NEURONAL CELL CONTAINING PROSTAGLANDIN F2α DERIVATIVE AS ACTIVE INGREDIENT
AU2020204384B2 (en) Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid
JP6888754B2 (en) Pharmaceutical product that forms a gel in situ
US20110105450A1 (en) Ophthalmic formulations of fluticasone and methods of use
JP2021138760A (en) Ophthalmologic preparation of cetirizine and methods of use
JP2018531292A6 (en) Pharmaceutical formulations that form gels in situ
JPH08509205A (en) Topical composition for the eye containing β-cyclodextrin derivative and therapeutic agent
JP2009519962A (en) Topical mecamylamine formulation for ophthalmic administration and use thereof
KR20110042282A (en) In situ gelling systems as sustained delivery for front of eye
Loftsson et al. Dexamethasone delivery to posterior segment of the eye
JP2019505587A (en) Betamethasone oral spray formulation and use for treatment of ataxia
WO2010137681A1 (en) Prophylactic or therapeutic agent for retinal diseases comprising tranilast, method for prevention or treatment of retinal diseases, and tranilast or pharmaceutically acceptable salt thereof and use thereof
JPWO2006098292A1 (en) Eye disease treatment
KR101587609B1 (en) Novel Ophthalmic Formulations Comprising beta-Cyclodextrin
JPH02262518A (en) Intraocular pressure-adjusting agent
JP2007056014A (en) Noninvasive drug delivery system to posterior part tissue of eye by using gel-like composition
CN115645420A (en) Application of mannose and medicinal derivatives thereof in preparation of medicines for preventing and/or treating age-related macular degeneration
IL311627A (en) Ophthalmic compositions and methods of using same
KR0159640B1 (en) Ophthalmic formulation containing dopamine receptor agonist for treatment of myopia and giaucoma
WO2007013591A1 (en) Non-invasive drug delivery system targeting posterior eye tissue using gel composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10836694

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2782015

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012543284

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13514769

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10836694

Country of ref document: EP

Kind code of ref document: A1